Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company
Home > Investor Relations > Press Releases

Press Releases

All Releases
View Summary Spectrum Pharmaceuticals Announces Publication of Pivotal EVOMELA™ (melphalan hydrochloride) for Injection Data in the Biology of Blood and Marrow Transplantation Journal
Sep 2, 2015
PDF 18.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Agreement with FDA on the Special Protocol Assessment (SPA) for the Upcoming Apaziquone Phase 3 Trial in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC)
Aug 17, 2015
PDF 16.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports Second Quarter 2015 Financial Results and Pipeline Update
Aug 6, 2015
PDF 43.8 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Second Quarter 2015 Financial Results Teleconference and Webcast
Jul 30, 2015
PDF 14.2 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Publication of Beleodaq® Data Selected as a Rapid Communication in the Journal of Clinical Oncology
Jun 24, 2015
PDF 72.6 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Five Abstracts of Clinical Data at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, May 29-June 2, 2015
May 29, 2015
PDF 15.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the Jefferies Global Healthcare Conference in New York City on June 3rd
May 28, 2015
PDF 13.4 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Commits to Review Shareholder Proposal
May 14, 2015
PDF 13.0 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports Continued Advancement of Robust, Late-Stage Pipeline and First Quarter 2015 Financial Results
May 7, 2015
PDF 83.9 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces First Quarter 2015 Financial Results Teleconference and Webcast
Apr 30, 2015
PDF 59.8 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Presents New Data on EVOMELATM (CE-Melphalan), at the Annual Meeting of the American Pharmacists Association (APhA) in San Diego, Highlighting Stability
Mar 30, 2015
PDF 63.2 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Reports Robust Clinical Data and Strong 2014 Financial Results
Mar 13, 2015
PDF 93.9 KB Add to Briefcase
View Summary Four Oncology Key Opinion Leaders to Present at Spectrum Pharmaceuticals' Analyst Day on Friday, March 13th
Mar 11, 2015
PDF 61.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan
Mar 9, 2015
PDF 62.7 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals In-Licenses Poziotinib, a Novel pan-HER Inhibitor With Clinical Activity in Several Solid Tumors, From Hanmi Pharmaceuticals
Mar 4, 2015
PDF 62.3 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals to Present Corporate Update at the 2015 RBC Capital Markets' Global Healthcare Conference on February 24th
Feb 20, 2015
PDF 59.0 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Announces Fourth Quarter 2014 Financial Results and Analyst Day
Feb 17, 2015
PDF 61.5 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights Clinical Data for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan at the 2015 BMT Tandem Meeting
Feb 12, 2015
PDF 65.0 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Files a New Drug Application with the FDA for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan
Dec 26, 2014
PDF 61.1 KB Add to Briefcase
View Summary Spectrum Pharmaceuticals Highlights 11 Abstracts at the 56th Annual Meeting of the American Society of Hematology (ASH) in San Francisco, California, December 6-9, 2014
Dec 5, 2014
PDF 29.7 KB Add to Briefcase
Showing 1-20 of 654 Page: 1 2 3 4 5 ... 33  Next 20
Add to Briefcase = add release to Briefcase

Back to top

Spectrum Pharmaceuticals, Inc. An International Commercial-Stage Biotechnology Company

NASDAQ: SPPI

Price:
6.62
Change:
- 0.40
Day High:
7.35
Day Low:
6.50
Volume:
3,479,700
4:00 PM ET on Sep 2, 2015
Delayed at least 20 minutes.
Provided by eSignal.

Shareholder Tools

Print Email

Search IR